If you have been taking Myfortic, have you been switched to generic Myfortic?

By Mike Sosna
Published on June 10, 2014

Check with your physcian if you are switched to generic Myfortic. Mylan announced the launch of Mycophenolic Acid Delayed-Release Tablets, the generic version of Novartis’ Myfortic.

Mycophenolic Acid is an immunosuppressant indicated for the prophylaxis of organ rejection in adults receiving kidney transplant, and for the prophylaxis of organ rejection in pediatric patients >5 years who are at least 6 months post kidney transplant. Mycophenolic Acid exhibits a cytostatic effect on T- and B-lymphocytes by inhibiting inosine monophosphate dehydrogenase (IMPDH). Blocking this pathway inhibits de novo guanosine nucleotide synthesis, therefore suppressing T- and B-lymphocyte proliferation. Mylan’s Mycophenolic Acid Delayed-Release Tablets are available in 180mg and 360mg dosage strengths.